… may abort migraine. … and selective CGRP receptor antagonists, the importance of CGRP
in the pathophysiology of migraine and the therapeutic principle of CGRP receptor antagonism …

… Therefore, we propose that current antimigraine drugs may reach sites in the dura mater
and the trigeminal ganglion, but not in the CNS apart from regions lacking a BBB. Moreover, …

… peptide (CGRP) receptor antagonist that is as effective as triptans in the acute treatment of
… This review will address the likely mechanisms and therapeutic potential of CGRP receptor …

… CGRP that is released from the trigeminovascular system or attached to CGRP receptors
during the migraine … action of CGRP and CGRP receptor interacting agents in migraine therapy …

… These characteristics make the small molecule CGRP receptor antagonists promising
antimigraine drugs. Another advantage of both ubrogepant and atogepant is their increased …

… of its antimigraine action remains unclear [… of drugs joined the repertoire of antimigraine
treatment. Rimegepant and ubrogepant are CGRP receptor antagonists, while humanized CGRP …

… attacks and can trigger migraine in patients, and CGRP receptor antagonists can abort
migraine. We also examine whether other drugs, such as triptans, might exert their antimigraine …

… treatments to the innovative CGRP target drugs that are … migraine and details on the
characteristic, function, and localization of CGRP to then focus on CGRP receptor antagonists (CGRP…

… Based on the role of CGRP in migraine, and the desire for a nonvasoconstrictor treatment,
CGRP receptor antagonism was proposed as a potential therapeutic target. CGRP 8-37 was …

… drug acts through a novel antimigraine mechanism by blocking the action of CGRP on the
CGRP-receptor … In the study telcagepant had an antimigraine effect that was not significantly …